154403-85-7

Usage

Uses

Used in Pharmaceutical Industry:
3-Pyridineacetonitrile,6-methoxy-(9CI) is used as an intermediate in the synthesis of pharmaceuticals for its potential role in the development of new drugs. Its unique chemical structure allows it to be a building block in the production of various functional materials, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical industry, 3-Pyridineacetonitrile,6-methoxy-(9CI) is utilized as an intermediate in the synthesis of agrochemicals. Its properties make it a valuable component in the development of new compounds for agricultural applications, such as pesticides and herbicides, to improve crop protection and yield.
Used in Organic Compounds Synthesis:
3-Pyridineacetonitrile,6-methoxy-(9CI) is also used as an intermediate in the synthesis of other organic compounds. Its versatile chemical structure allows it to be incorporated into a wide range of molecules, making it a valuable asset in the field of organic chemistry and the development of new materials with various applications.

Upstream product

• 13472-85-0 2-methoxy-5-bromopyridine 
• 58584-63-7 (6-methoxypyridin-3-yl)methanol 
• 151-50-8 potassium cyanide 
• 13472-56-5 2-methoxy-5-methylpyridine 
• 128632-03-1 5-(bromomethyl)-2-methoxypyridine 
• 7677-24-9 trimethylsilyl cyanide 
• 773837-37-9 sodium cyanide 
• 101990-70-9 2-methoxy-5-pyridylmethyl chloride 
• 26218-80-4 6-methoxy-nicotinic acid methyl ester 
• 943541-26-2 sulfuric acid 6-methoxypyridin-3-ylmethyl ester methyl ester 
• 143-33-9 sodium cyanide 

Downstream Products

• 518354-94-4 (E)-3-(3-Fluorophenyl)-2-(6-methoxy-3-pyridyl)-2-propenenitrile 
• 1046833-18-4 4-[6-(3-fluoro-phenyl)-pyridin-3-yl]-1-aza-bicyclo[2.2.1]heptane 
• 1046834-15-4 4-[6-(3-pyrazol-1-yl-phenyl)-pyridin-3-yl]-1-aza-bicyclo[2.2.1]heptane 
• 1047405-02-6 4-[6-(2-methoxy-phenyl)-pyridin-3-yl]-1-aza-bicyclo[2.2.1]heptane 
• 902130-87-4 2-(6-methoxypyridin-3-yl)acetic acid 

Relevant academic research and scientific papers

Pyridineacetamide derivative serving as CDK inhibitor, and preparation method and application thereof

The invention belongs to the technical field of pyridineacetamide derivatives, and particularly relates to a pyridineacetamide derivative serving as a CDK inhibitor and a preparation method and application of the pyridine acetamide derivative. The pyridineacetamide derivative shows excellent CDK9/CDK7 enzyme inhibitory activity, and can be used for preparing drugs used for treating cancers, especially hematologic cancers including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like and solid tumors such as breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.

Inhibitors of protein kinases

Compounds of general Formula (I): wherein R1, R2, R3, Ra, A, B and x are as defined herein are inhibitors of protein kinases in particular members of the cyclin-dependent kinase family and/or the glycogen synthase kinase 3 family and are useful in preventing and/or treating any type of pain, inflammatory disorders, cancer, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases, metabolic disorders, renal diseases, neurologic and neuropsychiatric diseases and neurodegenerative diseases.

Synthesis of bridgehead-substituted azabicyclo[2.2.1]heptane and -[3.3.1]nonane derivatives for the elaboration of α7 nicotinic ligands

Azabicyclo[2.2.1]heptane and -[3.3.1]nonane scaffolds (X = Cl, Br) containing a pyridinyl substituent at the bridgehead position were prepared via two complementary chemical pathways, either by the transformation of a methoxy group into a synthetically valuable chlorine atom at the C-6 position of the pyridine moiety or by means of a regioselective C-6 deprotonation/halogenation process of the pyridine moiety exemplified by chlorination or bromination. These newly generated scaffolds were then engaged in Suzuki-Miyaura coupling reactions to provide α7 nicotinic ligands. Both chemical series were evaluated in vitro for their affinity at α7 nicotinic receptors, revealing nanomolar potency with significant selectivity over the α4Β2 nicotinic subtype. These approaches offer a general access to these α7 nicotinic scaffolds and ligands.

Synthesis of new bridgehead substituted azabicyclo-[2.2.1]heptane and -[3.3.1]nonane derivatives as potent and selective α7 nicotinic ligands

New azabicyclo[2.2.1]heptane and -[3.3.1]nonane derivatives containing a pyridinyl substituent at the bridgehead position have been synthesized via an efficient ten chemical steps pathway. Both chemical series were then evaluated in vitro for their affinity at α7 nicotinic receptors revealing nanomolar potency with notably excellent selectivity over the α4β2 nicotinic subtype.

PYRIDINYL CARBAMATES AS HORMONE-SENSITIVE LIPASE INHIBITORS

Novel substituted pyridinyl carbamates of general formula (I):, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to hormone sensitive lipase. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which modulation of the activity of hormone sensitive lipase is beneficial.

PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF

The present invention provides a novel pyrimidine compound having an excellent adenosine receptor (A1, A2A, A2B receptor) antagonistic action. More specifically, it provides a compound represented by the following formula, a salt thereof or a solvate of them. In the formula, R1 and R2 are the same as or different from each other and each represents a hydrogen atom, an alkyl group having one to six carbon atoms which may be substituted, an alkenyl group having two to six carbon atoms which may be substituted, an alkynyl group having two to six carbon atoms which may be substituted, a cycloalkyl group having three to eight carbon atoms which may be substituted, a cycloalkenyl group having three to eight carbon atoms which may be substituted, a 5 to 14-membered non-aromatic heterocyclic group which may be substituted, an aromatic hydrocarbon cyclic group having six to fourteen carbon atoms which may be substituted, a 5 to 14-membered aromatic heterocyclic group which may be substituted, an acyl group having one to six carbon atoms which may be substituted or an alkylsulfonyl group having one to six carbon atoms which may be substituted; R3 represents a hydrogen atom, a halogen atom, a cyano group, an alkyl group having one to six carbon atoms which may be substituted, an alkenyl group having two to six carbon atoms which may be substituted, an alkynyl group having two to six carbon atoms which may be substituted, an aromatic hydrocarbon cyclic group having six to fourteen carbon atoms which may be substituted, a 5 to 14-membered aromatic heterocyclic group which may be substituted, a nitrogen atom which may be substituted, an oxygen atom which may be substituted or a sulfur atom which may be substituted; R4 represents an aromatic hydrocarbon cyclic group having six to fourteen carbon atoms which may be substituted, a 5 to 14-membered aromatic heterocyclic group which may be substituted or a 5 to 14-membered non-aromatic heterocyclic group having at least one or more unsaturated bonds which may be substituted; and R5 represents an aromatic hydrocarbon cyclic group having six to fourteen carbon atoms which may be substituted or a 5 to 14-membered aromatic heterocyclic group which may be substituted.